Synairgen PLC's (LON:SNG) chief executive Richard Marsden talks to Proactive London’s Katie Pilbeam about what has been achieved over the past six months.
The Phase III trial of its SNG001 inhaled, broad-spectrum antiviral is progressing well with top line results expected in early 2022.
Its clinical trial team, working alongside clinical research organization Parexel, has gained trial approvals in 17 countries and initiated over 100 trial sites despite the challenges posed by Coronavirus (COVID-19)-related restrictions. SNG001 is designed to treat COVID-19 amongst other conditions.